Retinal vein changes in patients with high-risk proliferative diabetic retinopathy treated with conbercept and panretinal photocoagulation co-therapy: a cohort study
Authors:
Open Access
- 25 August 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1218442
Abstract
Objective: This study aimed to observe and compare retinal vein diameter changes and other essential indicators in patients with high-risk proliferative diabetic retinopathy (PDR) treated with intravitreal injection of conbercept (IVC) combined with panretinal photocoagulation (PRP) versus PRP monotherapy.Methods: A retrospective analysis was conducted on data from patients with high-risk PDR who received specific treatment and were followed up for 24 months. Among 82 patients with high-risk PDR, 50 eyes received PRP combined with IVC, whereas 32 eyes received PRP alone. During the 24-month follow-up period, changes in best-corrected visual acuity (BCVA), central foveal thickness (CFT), retinal vein diameter, number of microaneurysms (MA), neovascularization (NV) area, hard exudate (HE) area, size of the foveal avascular zone (FAZ), superficial capillary plexus (SCP) blood flow density, and adverse effects were recorded and compared between the two groups at baseline and at 6, 12, 18, and 24 months after treatment. The relationship between each observation index and vein diameter was also analyzed.Results: During the 24-month follow up, significant improvements in the BCVA, CFT, retinal vein diameter, number of MAs, NV area, HE area, FAZ, and SCP were observed in the IVC+PRP group after treatment. The PRP group only showed significant reductions in NV and HE areas. The IVC+PRP group showed significant superiority over the PRP group in improving the vein diameter, number of MA, and HE area. However, no statistically significant difference in NV area reduction was found between the groups.Conclusion: In the treatment of high-risk PDR, IVC+PRP therapy has a significant advantage over PRP monotherapy. IVC+PRP therapy may reverse diabetes-induced retinal vein changes, restoring morphology and function.Keywords
This publication has 38 references indexed in Scilit:
- Epidemiology of diabetic retinopathy, diabetic macular edema and related vision lossEye and Vision, 2015
- Effects of Intravitreal Ranibizumab on Retinal Hard Exudate in Diabetic Macular EdemaOphthalmology, 2015
- Anti-vascular endothelial growth factor for proliferative diabetic retinopathyCochrane Database of Systematic Reviews, 2014
- Changes in Retinal Vessel Diameter and Incidence and Progression of Diabetic RetinopathyArchives of Ophthalmology (1950), 2012
- Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin‐induced diabetic ratsDiabetes, Obesity and Metabolism, 2012
- Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathyActa Ophthalmologica, 2011
- Diabetic retinopathyThe Lancet, 2010
- Diabetic RetinopathyNew England Journal of Medicine, 2004
- Subretinal Fibrosis in Diabetic Macular EdemaArchives of Ophthalmology (1950), 1997
- INDICATIONS FOR PHOTOCOAGULATION TREATMENT OF DIABETIC RETINOPATHY: DIABETIC RETINOPATHY STUDY REPORT NO. 14International Ophthalmology Clinics, 1987